GSK Arzerra Approved (NYSE:GSK)
Source: http://feedproxy.google.com/~r/FavStocks/~3/jmYsbuIaC8A/Posted on Tuesday, October 27th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.
GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related consumer products. However, the principal pharmaceutical products include medicines in the therapeutic areas such as respiratory, central nervous system, cardiovascular and urogenital, metabolic, vaccines and oncology and emesis. On the other hand Genmab is a Denmark-based biopharmaceutical company that is into the development of human antibodies for the treatment of life-threatening and dangerous diseases. The company develops many oncology products and other products related to cancer and other conditions related to it.
Arzerra has been approved under FDA’s accelerated approval mechanism that will allow both the companies to obtain approval for products based on less clinical data than typically required for a normal approval. However, FDA mentioned that accelerated approval requires further study of the drug and noted that GSK is currently conducting a clinical trial in CLL patients to confirm that Arzerra can help delay the progression of the disease when given with standard chemotherapy.
Last 5 posts by Mike Brown
- Lifeline Estimates Six Months For FDA Response (PINK:LLBO) - October 26th, 2009
- Alcon Takes Over Potentia (NYSE:ACL) - October 26th, 2009
- FDA approves GSK’s Votrient (NYSE:GSK) - October 20th, 2009
- Acorda Trading Halted (NASDAQ:ACOR) - October 16th, 2009
- Vanda Inks Novartis Deal (NASDAQ:VNDA) - October 14th, 2009
antibodies, Biopharmaceutical, Biotech, cancer, Chemotherapy, chronic lymphocytic leukemia, consumer products, Denmark, FavStocks, Food And Drug Administration, Genmab A/S;, Glaxosmithkline Plc, healthcare, Investing Lessons, leukemia, Leukemia Treatment, Oncology, oncology products;, Pharmaceutical Products, Stocks to Watch, treatment of life-threatening and dangerous diseases, Vaccines
 About Mike Brown (http://www.favstocks.com)
Born and raised in California. Mike studied business law and has been in the credit industry for over half a decade. Mike has been extremely active in the industry working directly with large financial institutions such as American Express. Prior, Mike held various management positions and developed strategic relationships with business such as Oakley. Investing started as a a hobby for Mike. Due to his recent success in the market he has amassed a fortune as a private self investor. His favorite sector is Credit/Finance and Biotech and through the knowledge Mike has gained over the years he will help you gain an insight into these industries and its competitive dynamics. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.